NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more
NanoViricides Inc (NNVC) - Total Assets
Latest total assets as of September 2025: $8.36 Million USD
Based on the latest financial reports, NanoViricides Inc (NNVC) holds total assets worth $8.36 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NanoViricides Inc - Total Assets Trend (2006–2025)
This chart illustrates how NanoViricides Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NanoViricides Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
NanoViricides Inc's total assets of $8.36 Million consist of 18.9% current assets and 81.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $317.04K | 3.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how NanoViricides Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NanoViricides Inc's current assets represent 18.9% of total assets in 2025, a decrease from 99.7% in 2006.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 91.9% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 3.6% of total assets.
NanoViricides Inc Competitors by Total Assets
Key competitors of NanoViricides Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
NanoViricides Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - NanoViricides Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - NanoViricides Inc is currently not profitable relative to its asset base.
NanoViricides Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 2.48 | 54.49 |
| Quick Ratio | 1.06 | 2.48 | 54.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $70.18K | $ 2.41 Million | $ 18.15 Million |
NanoViricides Inc - Advanced Valuation Insights
This section examines the relationship between NanoViricides Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.01 |
| Latest Market Cap to Assets Ratio | 2.22 |
| Asset Growth Rate (YoY) | -31.2% |
| Total Assets | $8.82 Million |
| Market Capitalization | $19.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NanoViricides Inc's assets at a significant premium ( 2.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: NanoViricides Inc's assets decreased by 31.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NanoViricides Inc (2006–2025)
The table below shows the annual total assets of NanoViricides Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $8.82 Million | -31.18% |
| 2024-06-30 | $12.82 Million | -24.12% |
| 2023-06-30 | $16.90 Million | -28.07% |
| 2022-06-30 | $23.49 Million | -22.36% |
| 2021-06-30 | $30.26 Million | +26.54% |
| 2020-06-30 | $23.91 Million | +77.82% |
| 2019-06-30 | $13.45 Million | -27.49% |
| 2018-06-30 | $18.55 Million | -31.32% |
| 2017-06-30 | $27.00 Million | -26.29% |
| 2016-06-30 | $36.63 Million | -17.09% |
| 2015-06-30 | $44.19 Million | -0.86% |
| 2014-06-30 | $44.57 Million | +171.64% |
| 2013-06-30 | $16.41 Million | +4.98% |
| 2012-06-30 | $15.63 Million | +45.28% |
| 2011-06-30 | $10.76 Million | +19.64% |
| 2010-06-30 | $8.99 Million | +199.62% |
| 2009-06-30 | $3.00 Million | +104.41% |
| 2008-06-30 | $1.47 Million | +8.74% |
| 2007-06-30 | $1.35 Million | -50.53% |
| 2006-06-30 | $2.73 Million | -- |